104632-27-1 Usage
Description
PRAMIPEXOLE HYDROCHLORIDE is a pharmaceutical compound that acts as a dopamine receptor agonist. It is primarily used in the treatment of Parkinson's disease and other related disorders. PRAMIPEXOLE HYDROCHLORIDE is available as a mixture of enantiomers, with the majority of its activity resulting from the (S) form. The (R) form of pramipexole, while less active as a dopamine receptor agonist, exhibits cytoprotective effects and has potential applications in conditions like amyotrophic lateral sclerosis.
Uses
Used in Pharmaceutical Industry:
PRAMIPEXOLE HYDROCHLORIDE is used as a secondary standard for quality control in pharmaceutical formulations. It serves as a certified reference material for various analytical applications, including pharmaceutical release testing, method development for qualitative and quantitative analyses, and calibration requirements.
PRAMIPEXOLE HYDROCHLORIDE is used as an analytical tool for the determination of the analyte in pharmaceutical formulations using reversed-phase high-performance liquid chromatography and ultraviolet spectrophotometry techniques.
Used in Quality Control:
PRAMIPEXOLE HYDROCHLORIDE is used as a pharmaceutical secondary standard, providing a convenient and cost-effective alternative to the preparation of in-house working standards for pharmaceutical laboratories and manufacturers.
Used in Parkinson's Disease Treatment:
PRAMIPEXOLE HYDROCHLORIDE is used as a dopamine receptor agonist for the treatment of Parkinson's disease, helping to manage the symptoms and improve the quality of life for patients.
Used in Research:
(R)-PRAMIPEXOLE HYDROCHLORIDE is used as a negative control for the (S) form in the study of dopamine receptors, providing valuable insights into the receptor's activity and potential therapeutic applications.
Used in Amyotrophic Lateral Sclerosis (ALS) Research:
The cytoprotective effect of (R)-PRAMIPEXOLE HYDROCHLORIDE, without dopaminergic side effects, suggests its potential utility in the study and treatment of amyotrophic lateral sclerosis.
Biochem/physiol Actions
R-(+)-Pramipexole is a neuroprotective agent; weak non-ergoline dopamine agonist. R-(+)-Pramipexole has been found to have neuroprotective effects and is being investigated for treatment of ALS. It reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, R-(+)-Pramipexole has much lower dopamine agonist activity.
Check Digit Verification of cas no
The CAS Registry Mumber 104632-27-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,6,3 and 2 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 104632-27:
(8*1)+(7*0)+(6*4)+(5*6)+(4*3)+(3*2)+(2*2)+(1*7)=91
91 % 10 = 1
So 104632-27-1 is a valid CAS Registry Number.
104632-27-1Relevant articles and documents
FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE
-
Paragraph 0317-0318, (2013/03/26)
The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.
IMPROVED SYNTHESIS OF AMINE SUBSTITUTED 4,5,6,7-TETRAHYDROBENZOTHIAZOLE COMPOUNDS
-
, (2013/07/05)
The present invention is related to an improved process for the preparation of amino- substituted 4,5,6,7-tetrahydrobenzothiazole compounds of formula I, such as the compound 2- amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention furthe
PROCESS FOR THE PREPARATION OF PRAMIPEXOLE AND NEW ANHYDROUS FORMS OF ITS DIHYDROCHLORIDE
-
Page/Page column 11-12, (2010/11/24)
The present invention provides processes for the preparation of (-) pramipexole or an acid addition salt thereof of Formula I. The present invention further provides for the novel polymorphic Forms A and B of anhydrous pramipexole dihydrochloride.